Related Experiment Video
Updated: Aug 12, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Effect modification of hepatitis B viral load on the association between metabolic risk factors and hepatic steatosis
Michelle Y Shi1, Christopher Wong1, Tai-Ping Lee2
1Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
Insights
Metabolic risk factors, not hepatitis B viral load, significantly increase the odds of hepatic steatosis (HS) in patients with chronic hepatitis B (CHB) infection. This suggests metabolic factors drive HS severity in this population.
Area of Science:
- Hepatology
- Virology
- Metabolic Syndrome
Background:
- Chronic hepatitis B (CHB) and hepatic steatosis (HS) often coexist in patients with metabolic risk factors.
- The interplay between CHB viral load and HS severity in these patients remains unclear.
Purpose of the Study:
- To investigate whether hepatitis B viral load modifies the association between metabolic risk factors and the severity of HS in patients with CHB.
Main Methods:
- Retrospective cross-sectional study of adult patients with non-cirrhotic NAFLD and CHB infection.
- Analysis included descriptive statistics, multivariate regression, and testing for interaction between metabolic risk factors and hepatitis B viral load.
Main Results:
- Each additional metabolic risk factor significantly increased the odds of HS > stage 2 by 77% (OR 1.77).
- Detectable hepatitis B viral load was not associated with increased odds of HS > stage 2 (OR 1.00).
- No significant interaction was found between metabolic risk factors and hepatitis B viral load regarding HS severity (ROR 1.01).
Conclusions:
- Hepatitis B viral load does not appear to modify the association between metabolic risk factors and HS severity in CHB patients.
- Metabolic risk factors, rather than hepatitis B viremia, are the primary drivers of HS in this patient group.
Background:
It is not clear if chronic hepatitis B (CHB) infection potentiates the severity of hepatic steatosis (HS) in patients with metabolic risk factors. We tested for the effect modification of hepatitis B viral load on the association between metabolic risk factors and HS.
Methods:
In this retrospective cross-sectional study, we included adult subjects, who had non-cirrhotic nonalcoholic fatty liver disease and CHB infection with positive hepatitis B envelope antibody. We reported descriptive statistics, stratified by detectable and undetectable hepatitis B viral load, by Kruskal-Wallis Rank Sum Test and chi-square. We reported coefficients of two multivariate regression predicting odds of HS > stage 2, testing for interaction between metabolic risk factors and hepatitis B viral load.
Results:
When controlled for age, sex, and hepatitis B treatment, the odds of HS > stage 2 increased significantly by 77% for each additional metabolic risk factor [odds ratio (OR) 1.77, 95% confidence interval (CI): 1.20-2.69, P=0.005]. The odds of HS > stage 2 was not associated with detectable hepatitis B viral load (OR 1.00, 95% CI: 0.83-1.19, P=0.986). The association between the odds of HS > stage 2 and metabolic risk factors did not significantly change as hepatitis B viral load increased [ratio of odds ratio (ROR) 1.01, 95% CI: 0.94-1.08, P=0.839].
Conclusions:
Our study does not find evidence of effect modification of hepatitis B viral load on the association between metabolic risk factors and HS in non-cirrhotic and hepatitis B envelope antibody positive patients with CHB viral infection. It suggests that the odds of HS in CHB infected patients is affected by metabolic risk factors and not by hepatitis B viremia.
More Related Videos
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

